KD — Kyndryl Holdings, Inc. Stock Price, Chart & AI Report

Negative Apr 11, 2026 • 02:29 UTC GlobeNewswire Inc. • Rosen Law Firm

KYNDRYL DEADLINE: ROSEN, NATIONAL INVESTOR RIGHTS COUNSEL, Encourages Kyndryl Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 13 Deadline in Securities Class Action First Filed by the Firm – KD

Rosen Law Firm reminds investors who purchased Kyndryl Holdings securities between August 7, 2024 and February 9, 2026 of the April 13, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Kyndryl made false statements regarding its financial condition, internal controls, and ability to file timely quarterly reports, resulting in investor losses.

KD securities class action lead plaintiff deadline financial misstatement internal controls investor losses Form 10-Q filing

Sentiment note

The company is the subject of a securities class action lawsuit alleging material misstatements in financial statements, inadequate internal controls, and inability to timely file required regulatory reports. These allegations indicate serious compliance and financial reporting failures that have resulted in investor losses.

Negative Apr 10, 2026 • 17:56 UTC GlobeNewswire Inc. • Hagens Berman

INVESTOR DEADLINE: Kyndryl (KD) Investors with Substantial Losses Have Opportunity to Lead the Kyndryl Class Action Lawsuit– Hagens Berman

Hagens Berman has filed an expanded securities class action against Kyndryl Holdings (KD) alleging the company manipulated free cash flow metrics through undisclosed cash management practices to mask its true financial health. The lawsuit covers investors from August 1, 2024, to February 6, 2026. Following disclosure of an SEC investigation and the departure of the CFO and General Counsel on February 9, 2026, Kyndryl's stock plummeted 55% from $23.49 to $10.59 per share. The lead plaintiff deadline is April 13, 2026.

KD securities class action cash flow manipulation SEC investigation executive departure financial restatement investor losses misleading financial statements

Sentiment note

Company faces expanded securities litigation alleging fraudulent cash flow reporting, undisclosed unsustainable cash management practices, SEC investigation, executive departures (CFO and General Counsel), and a 55% stock price collapse following disclosure of misconduct.

Negative Apr 8, 2026 • 20:53 UTC GlobeNewswire Inc. • Hagens Berman

INVESTOR DEADLINE: Kyndryl (KD) Investors with Substantial Losses Have Opportunity to Lead the Kyndryl Class Action Lawsuit– Hagens Berman

Hagens Berman has filed an expanded securities class action against Kyndryl Holdings for allegedly manipulating free cash flow metrics through undisclosed cash management practices to mask financial weakness. The lawsuit covers investors from August 1, 2024 to February 6, 2026. Following an SEC investigation disclosure and executive departures on February 9, 2026, Kyndryl's stock plummeted 55% from $23.49 to $10.59 per share. The lead plaintiff deadline is April 13, 2026.

KD securities class action cash flow manipulation SEC investigation executive departure financial fraud shareholder losses misleading statements

Sentiment note

Company faces expanded class action lawsuit alleging manipulation of free cash flow metrics, undisclosed cash management practices, SEC investigation, sudden departure of CFO and General Counsel, and 55% stock price decline. These factors indicate serious financial and legal troubles.

Negative Apr 7, 2026 • 23:28 UTC GlobeNewswire Inc. • Glancy Prongay Wolke & Rotter Llp

Deadline Alert: Kyndryl Holdings, Inc. (KD) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Glancy Prongay Wolke & Rotter LLP announced a class action lawsuit against Kyndryl Holdings, Inc. on behalf of investors who purchased securities between August 1, 2024 and February 9, 2026. The lawsuit alleges that Kyndryl made materially false statements and failed to disclose material adverse facts about its business, including misstated financial statements, inadequate internal controls, and inability to timely file quarterly reports. The company's stock fell 54.9% on February 9, 2026 following announcements of executive departures and SEC enforcement inquiries. The deadline to file a lead plaintiff motion is April 13, 2026.

KD securities fraud class action lawsuit internal controls financial statements SEC enforcement stock price decline

Sentiment note

The company faces a securities fraud class action lawsuit alleging material misstatements, inadequate internal controls, and failure to disclose material adverse facts. Executive departures, SEC investigations, and a 54.9% stock price decline on the announcement date indicate serious operational and governance issues.

Negative Apr 7, 2026 • 19:45 UTC GlobeNewswire Inc. • Pomerantz Llp

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Kyndryl Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines – KD

Pomerantz Law Firm has filed class action lawsuits against Kyndryl Holdings, AMC Entertainment, and NuScale Power Corporation. Kyndryl faced a 55% stock price drop following disclosure of an SEC investigation into financial reporting and the departure of its CFO, General Counsel, and Global Controller. Investors with losses are urged to contact the firm by April 13, 2026, to potentially become lead plaintiffs.

KD AMC SMR class action lawsuit securities fraud SEC investigation financial reporting stock price decline

Sentiment note

Company faces SEC investigation into financial reporting, experienced sudden departure of key executives (CFO, General Counsel, Global Controller), and suffered a severe 55% stock price decline on the announcement date.

Negative Apr 7, 2026 • 16:00 UTC GlobeNewswire Inc. • Law Offices Of Howard G. Smith

DEADLINE ALERT for PSFE, INO, KD: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

Law Offices of Howard G. Smith announced securities fraud class action lawsuits against three publicly-traded companies: Paysafe Limited (PSFE) for undisclosed business risks and overstated guidance, Inovio Pharmaceuticals (INO) for deficient manufacturing and overstated regulatory prospects, and Kyndryl Holdings (KD) for misstated financial statements and inadequate internal controls. Lead plaintiff deadlines range from April 7-13, 2026.

PSFE INO KD securities fraud class action lawsuit lead plaintiff financial misstatement regulatory issues

Sentiment note

Allegations of materially misstated financial statements, inadequate internal controls, and inability to timely file required regulatory reports indicate fundamental governance and financial reporting failures.

Negative Apr 6, 2026 • 14:00 UTC GlobeNewswire Inc. • Schall Law Firm

KD Investors Have Opportunity to Lead Kyndryl Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is seeking investors who purchased Kyndryl Holdings securities between August 7, 2024 and February 9, 2026 to join a class action lawsuit alleging securities fraud. The lawsuit claims Kyndryl made false and misleading statements, materially misstated financial statements, and failed to maintain adequate internal controls over financial reporting.

KD securities fraud class action lawsuit financial misstatement internal controls investor losses SEC violations

Sentiment note

The company is the subject of a securities fraud lawsuit alleging material misstatements in financial statements, inadequate internal controls, and false public statements that caused investor losses.

Negative Apr 5, 2026 • 22:37 UTC GlobeNewswire Inc. • Rosen Law Firm

RARE DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - RARE

Rosen Law Firm has filed securities class action lawsuits against Ultragenyx Pharmaceutical, Kyndryl Holdings, and Vital Farms, urging investors with significant losses to secure legal counsel before upcoming deadlines. The Ultragenyx case alleges the company made misleading statements about setrusumab's effectiveness in treating Osteogenesis Imperfecta, claiming bone density increases did not correlate to reduced fracture rates as promised.

RARE KD VITL securities class action investor losses Ultragenyx Pharmaceutical Kyndryl Holdings Vital Farms

Sentiment note

Company is subject to securities class action lawsuit filed by Rosen Law Firm, indicating alleged investor harm and potential securities violations.

Negative Apr 5, 2026 • 22:28 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Kyndryl Holdings, Inc. Investors to Secure Counsel Before Important April 13 Deadline in Securities Class Action First Filed by the Firm – KD

Rosen Law Firm is urging investors who purchased Kyndryl Holdings securities between August 7, 2024 and February 9, 2026 to join a securities class action lawsuit. The lawsuit alleges that Kyndryl made false statements about its financial condition, lacked adequate internal controls, and was unable to timely file its quarterly report for Q4 2025. The deadline to serve as lead plaintiff is April 13, 2026.

KD securities class action Kyndryl Holdings financial statements internal controls lead plaintiff deadline investor compensation

Sentiment note

The company is the subject of a securities class action lawsuit alleging material misstatements in financial statements, inadequate internal controls, and inability to timely file required regulatory reports. These allegations indicate serious financial and operational issues that resulted in investor losses.

Negative Apr 4, 2026 • 15:21 UTC GlobeNewswire Inc. • Hagens Berman

KD 9-DAY DEADLINE ALERT: Kyndryl (KD) Facing Securities Class Action Amid 55% Stock Drop After Four Bombshell Disclosures – Hagens Berman

Hagens Berman has filed an expanded securities class action against Kyndryl Holdings for allegedly manipulating free cash flow metrics to conceal true financial condition. The company's stock plummeted 55% following disclosure of an SEC investigation into cash management practices and the departure of its CFO and General Counsel on February 9, 2026. Investors have until April 13, 2026, to move for Lead Plaintiff status.

KD securities class action free cash flow manipulation SEC investigation executive departure stock collapse cash management practices financial fraud

Sentiment note

Company faces securities litigation alleging fraudulent cash flow reporting, 55% stock price decline, SEC investigation into cash management practices, and sudden departure of CFO and General Counsel. Allegations suggest deliberate concealment of true financial condition through undisclosed and unsustainable cash management practices.

Negative Apr 3, 2026 • 16:41 UTC GlobeNewswire Inc. • Glancy Prongay Wolke & Rotter Llp

Deadline Alert: Kyndryl Holdings, Inc. (KD) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Kyndryl Holdings faces a securities fraud class action lawsuit after the company announced on February 9, 2026 that its CFO and General Counsel departed immediately, it cannot timely file its quarterly report, and it is under SEC investigation regarding cash management practices and internal controls. The stock fell 54.9% on the news. Investors have until April 13, 2026 to file a lead plaintiff motion.

KD securities fraud class action lawsuit internal controls SEC investigation material misstatement stock price decline lead plaintiff deadline

Sentiment note

The company faces serious allegations of securities fraud, material financial statement misstatements, inadequate internal controls, and SEC enforcement action. The stock experienced a severe 54.9% price decline following disclosure of executive departures and regulatory issues, indicating significant loss of investor confidence and substantial financial harm to shareholders.

Negative Apr 3, 2026 • 00:00 UTC GlobeNewswire Inc. • Kirby Mcinerney Llp

IBRX SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of ImmunityBio, Inc. Investors - Contact Kirby McInerney LLP by May 26, 2026

Kirby McInerney LLP has filed securities fraud class action lawsuits against ImmunityBio, Kyndryl Holdings, and Super Micro Computer on behalf of investors. ImmunityBio faces allegations that Executive Chairman Patrick Soon-Shiong materially overstated capabilities of its Anktivas immunotherapy product. The FDA issued a warning letter on March 24, 2026, stating the company's marketing materials were false or misleading, causing ImmunityBio's stock to decline 21.2%. Investors have until specified deadlines to request lead plaintiff appointment.

IBRX KD SMCI securities fraud class action lawsuit FDA warning letter misleading marketing stock decline

Sentiment note

Company is subject to a securities fraud lawsuit with investors encouraged to contact the law firm regarding losses, indicating material adverse events affecting shareholder value.